I wrote a paper on Patient-Reported Outcomes and treatment modalities

Question Answered step-by-step I wrote a paper on Patient-Reported Outcomes and treatment modalitiesfor patients with Irritable Bowel Syndrome. I would like to know if I answered the question of ethical, legal and regulatory concerns. I spent time on this information but I think I am not on target.  I have looked at this information and rewrote this paragraph so many times, I am confused as to whether I actually answered the question.Thank youIdentify ethical, legal, and regulatory concerns regarding this problem.One may think that a diagnosis of IBS does not have ethical concerns for patients.  Ethics is the value, integrity, and principles that patients and clinicians abide by. In the past decade, there has been an increase in the value of patients’ perspectives in clinical research. A notable challenge is establishing their validity, reliability, responsiveness,  and interpretation of PROs, and correct understanding is vital to health care decision-making. According to (Meerhoff et al., 2021), “The minimal important difference, a measure of the smallest change in a measure that patients consider important, can greatly facilitate judgments of the magnitude of effect on patient-reported outcomes. However, the credibility of minimal important difference estimates varies, and guidance on determining credibility is limited.” A conversation that the physician must conduct with the patient regarding treatment is risk vs. benefits. The patient is determined to follow a treatment that is not a wise clinical decision. PROs do not permit patients to dictate their care.  Clinicians who abide by the oath ‘do no harm’ because the medicine can create psychological, medical, and social disadvantages. (Ogden, 2016). As a stakeholder in their outcomes, patients must take part in the responsibility of their health care and realize they can deem their treatments as unsuccessful.  According to Social Security Administration,  a diagnosis of Irritable Bowel Syndrome is not on the list of approved disabilities. The complexity and severity of the disease and its symptoms can be debilitating for patients. Symptoms range from minor inconvenience to severely disabling that activities of daily living, work performance, and emotional stability are compromised. The person as a whole, mind-body, and spirit is reduced to being incapable of living a  quality of life. If patients can not work, they may be eligible for disability benefits, but this is a lengthy process, and legal counsel is beneficial. (Shane, 2018).   When clinicians consider a diagnosis of IBS, they need to be aware of malpractice liability. Judicious examination of a patient’s health assessment is vital since incomplete laboratory or radiographic markers specific for the disorder can lead to a malpractice claim. (Feld, 2003)The  American College of Gastroenterology developed guidelines for the evaluation and management of patients living in North America. A need for updated regulatory policies in IBS management prompted the American College of Gastroenterology to develop a Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. In addition, clinically relevant questionnaires were developed to guide research efforts for Diagnostic strategies, specific drugs, doses, and duration of therapy outlined in the  ACG  guideline (Lacy et al., 2021).  The FDA also issued guidelines for therapies for IBS that focus on global symptom improvement.  Health Science Science Nursing NURS 498 Share QuestionEmailCopy link Comments (0)